Prostate cancer and neuroendocrine differentiation

International Urology and Nephrology

Volumn 31, Issue 1, 1999, Pages 75-82

  Tan, M O ^a   Karaoglan U ^a   Celik B ^a   Ataoglu O ^a   Biri, H ^a   Bozkirli, I ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL RADIOGRAPHY; ADENOCARCINOMA; ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FINGER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; PHYSICAL EXAMINATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECTUM; TRANSRECTAL ULTRASONOGRAPHY; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROSECRETORY SYSTEMS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0032982323     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007175924082     Document Type: Article

References (24)

1. Denis, L. J.: Staging and prognosis of prostate cancer. Eur. Urol., S2, 13 (October 1993).
2. Narayan, P.: Neoplasms of the prostate gland. In: Tanagho, E. A., Mc Aninch, J. W. (eds): Smiths Textbook of Urology. Prentice-Hall International Inc. California 1992. 13th Edition. Chapter 22, pp. 392-412
3. Peters P. C.: Staging, clinical manifestations and indication for intervention in prostate cancer. In: H. Lepor, R. K. Lawson (eds): Prostate Disease. W. B. Saunders Company, Philadelphia 1993. Chapter 21, pp. 269-275.
4. Gleason D. F.: Histologic grading of prostatic carcinoma. In: D. G. Bostwick (ed.): Pathology of Prostate. Churchill Livingstone Inc., Edinburgh 1990, Chapter 6, pp. 86-93.
5. Cohen, R. J., Glezerson, G., Haffejee, Z.: Neuroendocrine cells: A new prognostic parameter in carcinoma of prostate. Br. J Urol., 68, 258 (1991).
6. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R., Reuter, V. E.: Characterization of neuroendocrine differentiation in benign prostate and prostatic adenocarcinoma. Cancer, 71, 12, 65 (June 1993).
7. Di Sant' Agnese, P. A.: Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic and therapeutic implications. Cancer, 70 (Suppl. 1), 254 (1992).
8. De Lellis, R. A., Dayal, L.: Neuroendocrine System. Histology for Pathologists (ed. Stephen S. Sternberg). Raven Press Ltd., New York 1992. Chapter 17, pp. 347-361.
9. Kazzaz, B. A.: Argentaffin and argyrophil cells in the prostate. J. Pathol., 112, 189 (1974).
10. Abrahamsson, P. A., Wadström, L. B., Alumets, J., Falkmer, S., Grimelius, M.: Peptide hormone and serotonin immunoreactive cells in normal and hyperplastic prostate glands. Pat. Res. Pract., 181, 675 (1986).
11. Bonkhoff, H., Wernert, N., Dhom, G., Remberger, K.: Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate, 19, 91 (1991).
12. Iwamura, M., Abrahamsson, P. A., Foss, K. A., Cockett, A. T. K.: Autocrine regulation of prostate cancer cell growth by parathyroid hormone related protein. J. Urol., 149, 4 (Suppl.) 33A (1992).
13. Hoosein, N. M., Logothetis, C., Chung, W. K.: Differential effects of peptide hormones bombesin, VIP and somatostatin analogue RC-160 on the invasive capacities of human prostatic carcinoma cell lines. J. Urol., 147, 4, 33A (1992).
14. Azzopardi, J. G., Evans, D. J.: Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium. J. Pathol., 104, 247 (1971).
15. Cohen, R. J., Glezerson, G., Haffejee, Z.: Prostatic carcinoma: Histological and immunological factors affecting the prognosis. Br. J. Urol., 66, 405 (1990).
16. Di Sant' Agnese, P. A., De Mesy Jensen, K.: Neuroendocrine differentiation in prostatic carcinoma. Hum. Pathol, 18, 849 (1987).
17. Ruiziveld de Winter, J. A., Trapman, J., Vermey, M., Mulder, E., Zegers, N. D., Van der Kwast, T. H.: Androgen receptor expression in human tissues: An immunohistochemical study. J. Histochem Cytochem., 39, 927 (1991).
18. Van der Kwast, T. H., Schalken, J., Ruiziveld de Winter, J. A., Van Vroonhoven, C. C. J., Mulder, E., Trapman, J.: Androgen receptors in endocrine therapy resistant prostate cancer. Int. J. Cancer, 48, 189 (1991).
19. Krijnen, J. L. M., Bogdanowicz, F. A. T., Seldenrijk, C. A., Mulder, P. G. H., Van der Kwast, T. H.: The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J. Urol., 158, 171 (July 1997).
20. Davis, N. S., Di Sant' Agnese, P. A.: Calcitonin levels and neuroendocrine cells in human prostate cancer. J. Urol., 143 (Suppl.), 337A (1990).
21. Falkmer, S., Askensten, U., Grimelius, P., Abrahamsson, P. A.: Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of prostate gland tumor progression. Acta Histochem. (Suppl.), 18, 127 (1990).
22. Casamento, B. J., Abrahamsson, P. A., Nakada, S. Y., Di Sant' Agnese, P. A., De Mery-Jensen, K., Cockett, A. T. K.: Prognostic significance of neuroendocrine differentiation in prostatic carcinoma. J. Urol., 147, 4, 33A (1992).
23. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R., Zhang Zuo-Feng, Bazinet, M., Hamdy, S. F., Reuter, V. E.: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol , 151, 914 (1994).
24. Allen, F. J., Van Velden, D. J., Heyns, C. F.: Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer. Br. J. Urol., 75, 751 (1995).